Ascofuranone 是一种具有口服活性的 Trypanosoma brucei brucei(TAO)抑制剂(Ki 值为 2.38 nM),可抑制 IGF-1 诱导的癌细胞迁移、侵袭、运动及肌动蛋白细胞骨架形成并发挥抗肿瘤作用,可用于肿瘤转移、非洲锥虫病、细菌感染、肺癌及肝细胞癌的相关研究。
产品编号: MS-R58250 CAS No.: 38462-04-3 分子式: C23H29ClO5 分子量: 420.93
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
2.5mg
询价
询价

产品描述

Ascofuranone 是一种具有口服活性的 Trypanosoma brucei brucei(TAO)抑制剂(Ki 值为 2.38 nM),可抑制 IGF-1 诱导的癌细胞迁移、侵袭、运动及肌动蛋白细胞骨架形成并发挥抗肿瘤作用,可用于肿瘤转移、非洲锥虫病、细菌感染、肺癌及肝细胞癌的相关研究。

生物实验数据

生物活性 Ascofuranone is an orally active inhibitor of Trypanosoma brucei brucei (TAO) with a Ki value of 2.38 nM that inhibits IGF-1-induced cancer cell migration, invasion, motility, and actin cytoskeleton formation while exerting antitumor effects, and it can be used in research related to tumor metastasis, African trypanosomiasis, bacterial infections, lung cancer, and hepatocellular carcinoma.
体外研究
(In Vitro)

Ascofuranone (1-20 μM;24 h) 以剂量依赖的方式降低 A549、PC3 和 MCF-7 癌细胞的细胞活力,但在浓度高达 20 μM 时,对 LL24 正常肺细胞仅表现出有限的细胞毒性。
Ascofuranone (10 μM;24 h) 可使 A549、PC3 和 MCF-7 癌细胞的基础侵袭能力以及 IGF-1 诱导的细胞侵袭能力降低约 0.5 倍,但以 10 μM 处理 24 h 时,不会改变 LL24 正常肺细胞的侵袭能力。
Ascofuranone (0.1-10 μM;预孵育 1 h 后与 IGF-1 共孵育 10 min) 可在 A549、PC3 和 MCF-7 癌细胞中剂量依赖性地抑制 IGF-1 诱导的 mTOR 磷酸化,并抑制 IGF-1 诱导的下游 mTOR 效应因子 p70S6K 和 4EBP1 的磷酸化。
Ascofuranone (10 μM;预孵育 1 h 后与 IGF-1 共孵育 4 h) 在 A549 和 PC3 癌细胞中以不依赖 IGF-1 的方式激活 AMPK 和 ACC 的磷酸化,实验条件为 10 μM 浓度、预孵育 1 h 后与 IGF-1 共孵育 4 h。
Ascofuranone (10 μM;预孵育 1 h 后与 IGF-1 共孵育 10 min) 在 A549 和 PC3 癌细胞中以不依赖 IGF-1 的方式,通过诱导 Raptor 在 Ser792 位点的磷酸化并调控 TSC2 的磷酸化来抑制 mTORC1 活性,实验条件为 10 μM 浓度、预孵育 1 h 后与 IGF-1 共孵育 10 min。
Ascofuranone (1-10 μM;预孵育 1 h 后与 IGF-1 共孵育 10 min) 可呈剂量依赖性抑制 A549 和 PC3 癌细胞中 IGF-1 诱导的 FAK 磷酸化。
Ascofuranone (3 μM; 20 h) 可激活 U2OS 细胞中 PXR 的转录活性,其最低有效浓度为 3 μM。
Ascofuranone (IC50 3.2 μM; 48 h) 可抑制 U2OS 细胞增殖,其 IC50 为 3.2 μM。
Ascofuranone 可显著诱导 C3H10T1/2 细胞的脂肪细胞分化,且该过程不依赖于 PPARγ 激活。
Ascofuranone (50 nM) 可抑制表达 TAO 的 E. coli BL21 (DE3) pLysS 细胞质膜的泛醇氧化酶活性,使该活性降至未加抑制剂对照组的 31.6%。
Ascofuranone (50 nM) 单独使用时可抑制表达 TAO 的大肠杆菌 BL21 (DE3) pLysS 细胞质膜中琥珀酸依赖的耗氧活性的 23%,与 5 mM K+CN 联用时则可完全抑制该活性中氰不敏感的部分。
Ascofuranone (4-32 μg/mL) 对特定革兰氏阳性菌表现出强效抗菌活性,这些细菌包括金黄色葡萄球菌、耐甲氧西林金黄色葡萄球菌、表皮葡萄球菌和枯草芽孢杆菌,其 MIC 值范围为 4 至 32 μg/mL;同时该物质对白色念珠菌也具有抗菌活性,MIC 为 32 μg/mL,但对耐万古霉素粪肠球菌无活性 (MIC >128 μg/mL)。

Cell Viability Assay

Cell Line: LL24 normal lung cells, A549 lung cancer cells, PC3 prostate cancer cells, MCF-7 breast cancer cells
Concentration: 1-20 μM
Incubation Time: 24 h
Result: Did not decrease cell viability at doses lower than 5 μM, and resulted in approximately 90% cell viability at 20 μM in LL24 normal lung cells. Significantly decreased cell viability at 5 μM.

Cell Invasion Assay

Cell Line: LL24 normal lung cells, A549 lung cancer cells, PC3 prostate cancer cells, MCF-7 breast cancer cells
Concentration: 10 μM (co-incubated with IGF-1)
Incubation Time: 24 h (co-incubated with IGF-1)
Result: Did not significantly affect cell invasion in LL24 cells. Inhibited cell invasion by approximately 0.5-fold alone, and also significantly inhibited IGF-1-induced cell invasion in A549, PC3, and MCF-7 cancer cells.

Immunofluorescence

Cell Line: LL24 normal lung cells, A549 lung cancer cells, PC3 prostate cancer cells, MCF-7 breast cancer cells
Concentration: 10 μM (pre-incubated for 1 h, followed by 1 h co-incubation with IGF-1)
Incubation Time: 1 h pre-incubation, followed by 1 h co-incubation with IGF-1
Result: Did not alter F-actin distribution in LL24 cells. Did not change F-actin distribution alone, but prevented IGF-1-stimulated F-actin cytoskeleton organization at the leading edges of cells (lamellipodia and filopodia) in A549, PC3, and MCF-7 cancer cells.

Western Blot Analysis

Cell Line: A549 lung cancer cells, PC3 prostate cancer cells, MCF-7 breast cancer cells
Concentration: 0.1-10 μM (pre-incubated for 1 h, followed by 10 min co-incubation with IGF-1; mTOR analysis); 10 μM (pre-incubated for 1 h, followed by 10 min co-incubation with IGF-1; p70S6K and 4EBP1 analysis)
Incubation Time: 1 h pre-incubation, followed by 10 min co-incubation with IGF-1
Result: Significantly decreased IGF-1-induced mTOR phosphorylation in a dose-dependent manner across all three cancer cell lines. Suppressed IGF-1-induced phosphorylation of p70S6K and 4EBP1, downstream effectors of mTOR, in all three cell lines.

Western Blot Analysis

Cell Line: A549 lung cancer cells, PC3 prostate cancer cells
Concentration: 10 μM (pre-incubated for 1 h, followed by 4 h co-incubation with IGF-1)
Incubation Time: 1 h pre-incubation, followed by 4 h co-incubation with IGF-1
Result: Increased phosphorylation of AMPK and its downstream target ACC, irrespective of the presence of IGF-1. Resulted in phosphorylation of AMPK and ACC similar to that observed with ascofuranone alone in the presence of IGF-1.

Western Blot Analysis

Cell Line: A549 lung cancer cells, PC3 prostate cancer cells
Concentration: 10 μM (pre-incubated for 1 h, followed by 10 min co-incubation with IGF-1)
Incubation Time: 1 h pre-incubation, followed by 10 min co-incubation with IGF-1
Result: Decreased IGF-1-induced Akt phosphorylation in A549 and PC3 cells.
Significantly increased phosphorylation of Raptor at Ser792, a residue that inhibits mTORC1, in an IGF-1-independent manner. Suppressed IGF-1-induced TSC2 phosphorylation at Thr1462, and stimulated TSC2 phosphorylation at Ser1387.

Western Blot Analysis

Cell Line: A549 lung cancer cells, PC3 prostate cancer cells
Concentration: 10 μM (co-incubated with IGF-1)
Incubation Time: 12 h (co-incubated with IGF-1)
Result: Decreased IGF-1-stimulated binding of mTOR to Raptor (mTORC1 complex assembly), but did not alter assembly of the mTOR-Rictor (mTORC2) complex.
体内研究
(In Vivo)

Ascofuranone (50 mg/kg;腹腔注射;每 2 天 1 次;持续 28 天) 给药后,与溶媒对照组相比可使皮下 A549 异种移植瘤重量显著降低约 71%。
Ascofuranone (50 mg/kg; i.p.; once every two days; 6 weeks) 给药后,与对照组相比可显著减少 A549 肺转移,该效果与肺组织中 FAK 和 mTORC1 通路活性被抑制相关。

Animal Model: BALB/c nude (male, 6 weeks old, subcutaneous xenograft model via A549 cell inoculation)
Dosage: 50 mg/kg
Administration: i.p.; once every two days; 28 days
Result: Reduced average tumor weight to 0.386 g, compared to 1.33 g in vehicle-treated controls, representing a 71% reduction.
Animal Model: BALB/c nude (male, 6 weeks old, metastatic model via tail vein injection of A549 cells)
Dosage: 50 mg/kg
Administration: i.p.; once every two days; 6 weeks
Result: Reduced the number of metastatic lung nodules.
Decreased size and density of tumor cells in lung tissues via HE staining.
Suppressed Ki67 expression and significantly decreased phosphorylated mTOR levels in lung tissues via immunohistochemistry.
Confirmed suppressed phosphorylation of FAK and mTOR, and increased phosphorylation of Raptor in lung tissues via Western blot analysis, relative to vehicle control.
性状 油状物
颜色 Colorless to light pink

化学信息

分子量 420.93
分子式 C23H29ClO5
CAS No. 38462-04-3

储存&溶解度

储存方式
Pure form -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础